Clinical Trial Update: The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated etanercept (Enbrel) as the sole treatment for Grade I acute graft-versus-host disease, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Acute Graft Versus Host Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-08-04